SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and Tyra Biosciences (NASDAQ:TYRA – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Profitability
This table compares SAB Biotherapeutics and Tyra Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SAB Biotherapeutics | N/A | -0.36% | -0.31% |
| Tyra Biosciences | N/A | -41.17% | -38.40% |
Institutional and Insider Ownership
7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SAB Biotherapeutics | 1 | 1 | 5 | 1 | 2.75 |
| Tyra Biosciences | 1 | 0 | 10 | 1 | 2.92 |
SAB Biotherapeutics currently has a consensus target price of $11.00, indicating a potential upside of 177.78%. Tyra Biosciences has a consensus target price of $46.50, indicating a potential upside of 28.52%. Given SAB Biotherapeutics’ higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Tyra Biosciences.
Volatility and Risk
SAB Biotherapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
Earnings and Valuation
This table compares SAB Biotherapeutics and Tyra Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SAB Biotherapeutics | $1.32 million | 152.85 | $13.27 million | ($2.32) | -1.71 |
| Tyra Biosciences | N/A | N/A | -$119.95 million | ($2.01) | -18.00 |
SAB Biotherapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
SAB Biotherapeutics beats Tyra Biosciences on 7 of the 12 factors compared between the two stocks.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
About Tyra Biosciences
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
